Download lakewood-amedex, inc. appoints william j. robison, former executive

FOR IMMEDIATE RELEASE
LAKEWOOD-AMEDEX, INC. APPOINTS WILLIAM J. ROBISON, FORMER
EXECUTIVE VICE PRESIDENT OF PFIZER, AS BOARD MEMBER
Sarasota, Florida, March 10, 2009 – Lakewood-Amedex, Inc., (L-A), the anti-infectives
biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral
products including NuBiotics®, a novel family of synthetic anti-bacterial compounds,
announced today the appointment of William J. Robison, a former Pfizer senior executive, to
the company’s Board of Directors.
Mr. Robison most recently was an Executive Vice President of Pfizer, Inc.until he retired in
2001. He joined Pfizer, Inc. in 1961 and served within Pfizer’s pharmaceutical sales
organization to become Senior Vice President of Sales for Pfizer Labs. He was subsequently
named General Manager for Pratt Pharmaceuticals and in 1992 was named President of
Pfizer’s Consumer Healthcare Group and made a Pfizer Corporate Officer. In 1996 he joined
Pfizer’s Corporate Management Committee and was promoted to the position of Executive
Vice President and Head of Worldwide Corporate Employee Resources.
Mr. Robison currently serves as a director of several healthcare companies and is also on the
Board of Trustees of the University of Louisiana-Monroe. He is a Founding Member of the
United States Marine Corps Museum. Mr. Robison received a BS in Mathematics from the
University of Louisiana-Monroe.
Steve Parkinson, L-A’s President and Chief Executive Officer, commented “We’re delighted to
have this highly experienced and respected pharmaceutical professional on our Board. Mr.
Robison broadens our existing scientific and medical expertise and he will be especially
valuable as we start to develop strategic collaborations with potential large pharmaceutical
partners.”
Mr. Robison said “It is a great pleasure to be a part of an exciting and growing company like
Lakewood-Amedex. Its broad anti-bacterial and targeted anti-viral products hold great
promise for the healthcare industry and could save numerous lives in the future. At the
appropriate time we will aggressively seek pharmaceutical companies to work with us in the
commercial development of our products.”
About Lakewood-Amedex, Inc.
Lakewood-Amedex is a privately held development-stage biopharmaceutical company with a
broad patent portfolio of inventions, including, 24 granted and/or issued patents and 45 patent
applications covering its proprietary NuBiotics family of anti-microbial products, proven to be
effective against a wide range of bacteria, encompassing antibiotic resistant strains including
methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas and others, and patents
covering certain proprietary products targeting pandemic viral infections including, Epstein
Barr Virus (EBV), human and avian influenza, Hepatitis B and C and other clinical indications.
The Company anticipates initiating human clinical trials for topical use of its Nu-3 NuBiotics®
compound in the near future for indications including; diabetic ulcers and other topical
infections. Future studies will involve the use of Nu-2® to treat broad spectrum antibiotic-
resistant bacterial pulmonary and systemic infections. The company is currently conducting a
human IRB clinical study to improve treatment of nasopharyngeal carcinoma in Changsha,
China. Lakewood-Amedex is headquartered in Sarasota, FL.
###